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Drug development is a very laborious and expensive process. One of the major reasons for failure 
during the clinical phases of drug development is inadequate pharmacokinetic data on the drug 
candidate. Therefore, it would be advantageous if the pharmacokinetic properties of drug candidates be 
predicted beforehand. One major obstacle in making such predictions is the inability to appropriately 
scale the in-vitro data to the in-vivo situation. Results from in-vitro in-vivo correlation (IVIVC)  studies 
have been used to select the appropriate excipients and optimize the manufacturing processes for 
quality control purposes, and for characterizing the release patterns of newly formulated immediate 
release, and modified-release products relative to the references. In recent years, the concept and 
application of the IVIVC for pharmaceutical dosage forms have been a major focus of attention in the 
pharmaceutical industry, academia and regulatory agencies. Hence, this article highlights the 
importance of appropriate selection of IVIVC level with respect to the Biopharmaceutical Classification 
System (BCS) and also covers examples of BCS-based IVIVCs of drugs/products with different types of 
release profiles.  
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INTRODUCTION 
 
In recent years, the concept and application 
of the in vitro/in vivo correlation (IVIVC) for 
pharmaceutical dosage forms have been a 
main focus of the pharmaceutical industry, 
academia and regulatory bodies [1].  
 
A regulatory guidance for both immediate (IR) 
and modified release (MR) dosage forms 
has, therefore, been developed by United 
States Food and Drug Administration (FDA) 
to minimize the need for bioavailability 
studies as part of formulation design and 
optimization [2]. In vitro dissolution testing of 
solid oral dosage forms serves as a very 
important tool in drug development for 
selecting and optimizing formulations, 
studying drug-release mechanisms, ensuring 
batch-to-batch consistency, monitoring 
stability and demonstrating bioequivalence. 
Additionally, for the development of modified 
release (MR) dosage form. the focus of 
dissolution testing in the early stage of drug 
development is to provide predictive 
estimates of drug release in respect to in vivo 
performance of a drug product [3]. Thus no 
costly in vivo bioequivalence testing is 
required [4]. 
 
This review essentially addresses FDA 
guidelines for development, evaluation, and 
application of in vitro/in vivo correlations and 
highlights the importance of appropriate 
selection of IVIVC level with respect to 
Biopharmaceutical Classification System 
(BCS). The review also looks at examples of 
BCS based IVIVCs of drugs/products with 
different type of release profiles. 
 
IN VITRO/IN VIVO CORRELATIONS 
 
IVIVC has been defined by the FDA as “a 
predictive mathematical model describing the 
relationship between an in-vitro property of a 
dosage form and an in-vivo response” [4]. 
Generally; the in-vitro property is the rate or 
extent of drug dissolution or release while the 
in-vivo response is the plasma drug 
concentration or amount of drug absorbed. 
The United States Pharmacopoeia (USP) 
also defines IVIVC as “the establishment of a 
relationship between a biological property, 
and a parameter derived from a biological 
property produced from a dosage form, and a 
physicochemical property of the same 
dosage form” [5]. 
 
Developing the correlation 
 
The basic requirements for developing IVIVC 
are:  
• Data obtained from human studies are 
required for regulatory consideration of 
the correlation  
• Two or more drug product formulations 
with different release rates are developed 
and their in vitro dissolution profiles 
generated using an appropriate 
dissolution method 
• Usage of same dissolution method for all 
the formulations, and  
• Plasma concentration data from a 
bioavailability study for each of the 
formulations [6]. 
 
Categories of in vitro/in vivo correlations 
Level A 
 
Level A correlation is usually estimated by a 
two-stage procedure: deconvolution [7] 
followed by comparison of the fraction of drug 
absorbed to the fraction of drug dissolved. 
Correlation of this type is generally linear. 
Model Level A correlation is depicted in 




Level B uses the principles of statistical 
moment analysis. The mean in vitro 
dissolution time (MDT) is compared either to 
the mean residence time (MRT) or to the 




Level C establishes a single point relationship 
between a dissolution parameter, for 
example, t50%, percent dissolved in 4 h and a 
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pharmacokinetic parameter, e.g., AUC, Cmax 
































Figure 3: Model Level C for IVIVC between C max 
and percent drug dissolved at 8 hours [7] 
 
Multiple Level C 
 
A multiple Level C correlation relates one or 
several pharmacokinetic parameters of 
interest to the amount of drug dissolved at 
several time points of the dissolution profile.  
Various parameters used in IVIVC depends 
on the level, as depicted in Table1 [7]. 
 
Table 1: Various parameters used in IVIVC 
depending on the level [7] 
 
Level In vitro In vivo 
A Dissolution curve Input (absorption) 
curves 
B Statistical moments: 
MDT 
Statistical moments: 
MRT, MAT, etc 
C Disintegration time, 
time to have 10, 50, 
90% dissolved, 
dissolution rate and 
dissolution efficiency 
Cmax, Tmax, Ka, time 
to have 10, 50, 90% 
absorbed and AUC 
(total or cumulative) 
 
Key: MDT = mean dissolution time, MRT = mean 
residence time, MAT = mean absorption time 
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IVIVC models 
 
The most basic IVIVC models are expressed 
as a simple linear equation (Eq 1) between in 
vivo drug absorption and in vitro drug 
dissolved (released).  
 
Y  = mX + C ……………………………  (1) 
 
where Y is the in vivo absorbed and X the in 
vitro drug dissolved, m the slope of the 
relationship and Cthe intercept. Ideally, m = 1 
and C = 0, indicating a linear relationship. Eq 
1 may be applied to most formulations with 
comparable in vitro and in vivo profiles. 
However, for dosage forms with complicated 
mechanisms of release, which are usually of 
longer duration, in vitro release may not be 
on the same time scale as the in vivo release. 
Thus, in order to model such data, it is 
necessary to incorporate time-shifting and 




Validation is an important tool as it provides 
the confidence to accept a mathematical 
model. Here, IVIVC model validation can 
successfully predict the outcome (in vivo 
profile) with a given model and test condition 
(in vitro profile). Internal validation  [10] 
serves the purpose of providing the basis for 
the acceptability of the model, while external 
validation  [10] is superior and affords greater 




Using the IVIVC model, for each formulation, 
the relevant exposure parameters (Cmax and 
AUC) are predicted and compared to the 
actual (observed) values. The prediction 
errors are calculated using Eq 3. The criteria 
set in FDA guidlines on IVIVC are as follows: 
For Cmax and AUC, the mean absolute 
percent prediction error (% PE) should not 
exceed 10 %, and the prediction error for 
individual formulations should not exceed 15 
% [10]. 
Prediction   = [(Cmax observed – Cmax 
predicted) / Cmax observed]*100  ……. ….. (2) 
 
Error (%PE) = [(AUC observed – AUC 
predicted) / AUC observed]*100 ………… (3)     
                                                            
External validation [10] 
 
For establishing external predictability, the 
exposure parameters for a new formulation 
are predicted using its in vitro dissolution 
profile and the IVIVC model whereby the 
predicted parameters are compared to the 
observed parameters. The prediction errors 
are computed as for the internal validation. 
For Cmax and AUC, the prediction error for the 
external validation formulation should not 
exceed 10 %[11] A prediction error of 10 to 
20 % indicates inconclusive predictability and 
illustrates the need for further study using 
additional data sets. For drugs with narrow 
therapeutic index (TI), external validation is 
required despite acceptable internal 
validation, whereas internal validation is 





The biopharmaceutical classification system 
(BCS) is a scientific framework for classifying 
a drug substance based on its aqueous 
solubility and intestinal permeability.  
 
Characteristics of drugs in BCS [5] 
 
• Class I drugs exhibit a high absorption 
number and a high dissolution number.  
• Class II drugs have a high absorption 
number but a low dissolution number. 
• Class III drugs exhibit a high variation in 
the rate and extent of drug absorption. 
Permeability is rate limiting step for drug 
absorption.  
• Class IV drugs exhibit poor and variable 
bioavailability. 
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Estimation of IVIVC using the 
biopharmaceutical drug classification 
system 
 
BCS is a fundamental guideline for 
determining the conditions under which in-
vitro/in-vivo correlations are expected. It is 
also used as a tool for developing in-vitro 
dissolution specification [8]. In vitro-in vivo 
correlation is normally expected for highly 
permeable drugs or drugs under dissolution 
rate-limiting conditions. This statement is 
supported by the biopharmaceutical 
classification system, which anticipates 
successful IVIVC for highly permeable drugs 
[9]. Biopharmaceutical classification system 
and expected IVIVC for immediate release 
(IR) and extended release (ER) drug 
products are summarized in Tables 2 and 3, 
respectively.  
 
Highlights from some published works on IVIVCs 
in the context of BCS Classes I - IV are 
summarized in Table 4 - 6, respectively. 
 
Table 2: BCS and expected IVIVC for immediate release drug products [27] 
 
Class Solubility Permeability Absorption Expected IVIVC 
1 High High Gastric 
emptying 
controlled 
IVIVC is expected if dissolution rate is 
slower than gastric emptying rate, 
otherwise limited or no correlation 
2 Low High Dissolution 
controlled 
IVIVC is expected if in vitro dissolution 
rate is similar to in vivo dissolution 
rate, unless dose is very high 
3 High Low Dissolution 
independent 
Absorption (permeability) is rate 
determining; limited or no IVIVC with 
dissolution rate 
4 Low Low Case-by-case 
evaluation 
Limited or no IVIVC is expected 
 
Table 3: BCS and expected IVIVC for extended-release drug products [6] 
 
Class Solubility Permeability Expected IVIVC 
Ia High & Site 
Independent 
High & Site Independent Correlation 
(if dissolution is rate-limiting 
step) 
Ib High & Site 
Independent 
Dependent on site & Narrow 
absorption window 
IVIVC expected 
IIa Low & Site 
Independent 
High & Site Independent Variable 
IIb Low & Site 
Independent 
Dependent on site & Narrow 
absorption window 
Little or no IVIVC 
III High Solubility Low Permeability Little or no IVIVC 
IV Low Solubility Low Permeability Little or no IVIVC 
Vaa Variable Variable Little or no IVIVC 
Vba Variable Variable IVIVC Level A expected 
aDrugs that have variable solubility and variable permeability are classified as Class V. Class Va includes acidic drugs 
and Class Vb includes basic drugs 
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Table 4: Some IVIVC methods used for BCS Class I drugs 
 
Drug In-vitro evaluation 
In-vivo  
evaluation 
Level of  
IVIVC Reference 
Salbutamol Sulfate f2 test Wagner-Nelson 
method 
Level A  [12] 
Buspirone hydrochloride 
ER Tablets 
f2 test Wagner-Nelson 
method 
Level A [13] 
Metoprolol ER  f2 test Wagner-Nelson 
method 
Level A  [14] 
Metoprolol IR   Level B   





Level A [15]  




Level A  [16] 
Metoprolol Tartrate f2 test Wagner-Nelson 
Method  
Level A [17] 



































Key: FRD = fraction of drug dissolved; FRA = fraction of drug absorbed 
 
Biopharmaceutical Classification System 
(BCS) represents a criterion for the 
classification of drugs on the basis of their 
solubility and permeability. As per literature, 
several IVIVCs methodologies were followed 
according to the biopharmaceutical 
classification system for different 
drugs/products. 
 
To investigate the BCS class I drugs, 
(salbutamol, buspirone, metoprolol, 
naproxen, niacin, thyroxin, theophylline and 
nicotine) the evaluation of in-vitro profile 
demonstrated by comparison of dissolution 
profile, model-dependent approaches and 
similarity factor (f2-test) method. Wagner-
Nelson deconvolution, convolution and 
dermatopharmacokinetic (DPK) methods 
were used for in-vivo evaluation of BCS class 
I drugs/products. Regarding the level of 
IVIVC, point-point correlation (level-A), 
followed by multiple level-C and Michaelis-
Menten kinetics were used. Level A results 
revealed good correlations between in vitro 
drug release and in vivo drug absorption. 
Level B IVIVC also exhibited a strong linear 
relationship between mean residence time 
(MRT) and mean dissolution time (MDT).  
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 Table 5: Some IVIVCs methods used for BCS Class II drugs 
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Table 6: Some IVIVCs methods used for BCS Class III drugs 
 
Drug In vitro evaluation 
In vivo  
evaluation 














































Level C IVIVC did not show a perfect 
correlation, which may be due to single point 
correlation [40].   
 
In the case of BCS class II drugs (danazol, 
nifedipine, carbamazepine, piroxicam, 
nimesulide and griseofulvin), in vitro 
evaluation includes, flow-through dissolution 
test, application of Noyes-Whitney equation 
and comparison of dissolution profiles. For in 
vivo evaluation deconvolution, Wagner-
Nelson and non-compartmental analysis 
methods were successfully to determine in 
vivo performance. The in vitro results, 
compared with the in vivo data by means of 
level-A followed by level-C, correlated  
excellently for poorly soluble drugs/products. 
[41]. 
 
For BCS class III drugs (paracetamol, 
roxatidine, levothyroxine, pseudoephedrine, 
clonazepam and metformin), Similarity factor 
(f2 value) [42]  and comparison of dissolution 
profile were assessed to evaluate in-vitro 
drug release profile. In vivo evaluation was 
performed using numerical deconvolution, 
non-compartmental analysis and Wagner-
Nelson methods [43]. On the basis of 
correlation, level-A, followed by multiple level-
C demonstrate reliable and robust estimate of 
drug product performance.   
 
In-vitro evaluation of BCS Class IV drugs, 
such as lopinavir and remoxipride, was 
predicted by comparison of dissolution profile 
as well as by f-test. For in-vivo evaluation, 
Wagner-Nelson method and level A 
correlation exhibited perfect correlation 
between in-vitro and in-vivo comparison. 
 
APPLICATIONS OF IVIVC IN DRUG 
DELIVERY 
 
A main objective of developing and 
evaluating IVIVC is to establish the 
dissolution test as a surrogate for human 
bioequivalence studies. However, for the 
applications outlined below, the adequacy of 
the in vitro dissolution method to act as a 
surrogate for in vivo testing should be shown 
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through an IVIVC for which predictability has 
been established [41]. 
 
Early stages of drug delivery technology 
development: Proof-of-concept 
 
The selection of a drug candidate marks the 
most crucial stage in the life cycle of drug 
development. During this stage, exploring the 
relationship between in vitro and in vivo 
properties of the drug in animal models 
provides an idea of the feasibility of the drug 




Frequently, drug development requires 
changes in formulations due to a variety of 
reasons, such as unexpected problems in 
stability, development, availability of better 
materials, better processing results, etc. 
Having an established IVIVC can help avoid 
bioequivalence studies by using the 
dissolution profile from the changed 
formulation and subsequently predicting the 
in vivo concentration-time profile. This 
predicted profile could act as a surrogate of in 
vivo bioequivalence study.  
 
IVIVC and parenteral drug delivery 
 
IVIVC can be developed and applied to 
parenteral dosage forms, such as controlled-
release particulate systems, implants, etc, 
that are either injected or implanted. 
However, there are relatively fewer 
successes in the development of IVIVC for 
such dosage forms. 
 
Formulation assessment: in vitro 
dissolution 
 
A suitable dissolution method that is capable 
of distinguishing the performance of 
formulations with different release rates in 
vitro and in vivo is an important tool in 
product development. IVIVC facilitates the 
process of such method development [41]. 
Dissolution specifications 
 
The process of setting dissolution 
specifications in the presence of an IVIVC 
starts by obtaining the reference (pivotal 
clinical batch) dissolution profile. 
Specifications should optimally be 
established such that all batches with 
dissolution profiles between the fastest and 
slowest batches are bioequivalent and less 
optimally bioequivalent to the reference batch 
[42]. 
 
Increased development of modified release 
dosage forms necessitates investigating the 





Based on data from the literature, it is evident 
that current IVIVC studies have focused more 
on the development and validation of level A 
IVIVC which gives more useful information on 
the relationship between in vitro release and 
in vivo absorption from dosage form. Levels 
B and C IVIVCs have been evaluated for 
several purposes in formulation development, 
for example, to select the appropriate 
excipients and optimize the manufacturing 
processes, for quality control purposes and 
for characterizing the release patterns of 
newly formulated immediate release and 
modified-release products relative to the 
references. Present regulatory guidelines for 
IVIVC is only applicable to oral conventional 
and modified release dosage forms; however, 
further research is necessary to develop 
IVIVCs for non-oral products, inhaled 
medicines and dermatological medicaments. 
Also, it is possible that the IVIVC can still be 
explored to provide a greater understanding 
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